Recent meetings
No recorded meetings with EU commissioners.
Mission & Goals
Solidsoft Reply is a technology company working in the healthcare and pharmaceutical sectors. We built and run the European Medicines Verification System used to verify approximately ten billion packs of medicine across the EU each year at 160,000 points of dispense. We operate national medicine verification systems in 14 EU countries. We build verification and traceability systems used across the world, together with healthcare-related systems focused on patient and medicine safety. We work with non-profit organisations (UNICEF, USAID, GAVI, etc.), NGOs and the pharmaceutical industry combatting falsified and counterfeit medicines and reducing vaccine hesitancy in low- and middle-income countries. Based in the UK, we are part of the Reply Group of technology companies headquartered in Milan in Italy. Reply operates across the EU and other regions of the world.
EU Legislative Interests
Much of our work centres on two pieces of existing EU legislation: Directive 2011/62/EU amending Directive 2001/83/EC. This is commonly known as the Falsified Medicines Directive (FMD) Commission Delegated Regulation (EU) 2016/161 supplementing the FMD. The EU is currently engaged in a major review of Directive 2001/83/EC with a view to introducing new and updated legislation which we expect to affect our work in medicines verification and traceability. To date, our main communication with the EU is via the European Medicines Verification Organization (EMVO), a stakeholder non-profit organisation mandated by EU law and headquartered in Brussels. Going forward, we are currently planning to support and participate in the European Critical Medicines Alliance announced by the Health Emergency Preparedness and Response Authority (HERA) with a specific interest in addressing medicine shortages across the Union.
Communication Activities
In addition to our Web Site, we contribute regularly to thought leadership and discussion via Linked-In and attend various pharmaceutical events with a focus on medicine safety and verification.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
GS1 Partner https://www.gs1uk.org/partner-finder
Connected Legislation
Amendment: Annex II to Regulation (EU) 2019/6
Regulation on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans
Correction: Delegated Regulation (EU) 2021/577 (Veterinary medicinal products)
Supplementing Regulation (EU) 2019/6: Single lifetime identification document
Regulation on the volume of sales and on the use of antimicrobial medicinal products in animals
Veterinary medicinal products
Regulation on appropriate measures to ensure the effective and safe use of veterinary medicinal products authorised and prescribed for oral administration via routes other than medicated feed and administered by the animal keeper to food-producing animals
Prohibition of certain antimicrobial products in animal imports
Amendment to Regulation (EU) 2019/6 on compliance with good laboratory practice for veterinary medicinal products set out in Annex II to that Regulation